Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:SMMT

Summit Therapeutics Q3 2026 Earnings Date & Estimates

Summit Therapeutics logo
$15.35 +0.02 (+0.15%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Summit Therapeutics is estimated to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. The conference call is scheduled for 7:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
7:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Summit Therapeutics in Q3 2026

Summit Therapeutics is expected to post earnings of -$0.2806 per share on revenue of $71 thousand. In the same quarter a year earlier Summit Therapeutics reported -$0.31 per share. Summit Therapeutics last reported on July 23, 2026, posting -$0.28 per share and missing the -$0.2744 consensus estimate. Summit Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.2806
Expected Revenue
$71 thousand
Prior-Year EPS
-$0.31

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.28 (Missed by -$0.0056)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Summit Therapeutics Q3 2026 Earnings FAQ

Summit Therapeutics (NASDAQ:SMMT) is estimated to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Summit Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Summit Therapeutics to post earnings of -$0.2806 per share for Q3 2026.

The consensus revenue estimate for Summit Therapeutics is $71 thousand for Q3 2026.

Summit Therapeutics Earnings Headlines

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
October 25 at 4:00 PM  |  gurufocus.comhttps://www.gurufocus.com/news/9141425/ivonescimab-plus-chemotherapy-demonstrates-overall-survival-superiority-compared-to-durvalumab-plus-chemotherapy-in-firstline-treatment-of-patients-with-advanced-biliary-tract-cancer-in-harmonigi1-s
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
October 25 at 11:52 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261025603151/en/ivonescimab-plus-chemotherapy-demonstrates-overall-survival-superiority-compared-to-durvalumab-plus-chemotherapy-in-first-line-treatment-of-patients-with-advanced-biliary-tract-cancer-in-harmoni-gi1-study-conducted-by-akeso-in-china/
Your book is inside
Blane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn 100 Into 1000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.tc pixel
October 28 at 1:00 AM  |  TradeWins (Ad)
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
October 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development-302918571.html
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
October 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261023155751/en/summit-therapeutics-and-lunit-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development/
Summit Therapeutics PLC (NASDAQ:SMMT) Stock Rated "Moderate Buy" by Wall Street Brokerages
October 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31144891
See More Summit Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email.

About Summit Therapeutics

Summit Therapeutics (NASDAQ:SMMT) Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company’s primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases.

Summit’s lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings.

Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company. Akeso retains rights in China, while Summit is responsible for development and commercialization activities across its licensed international territories.

The company has roots in the United Kingdom and was historically involved in developing treatments for infectious diseases before shifting its strategic focus to oncology. Summit is led by Robert W. Duggan, who serves as chairman and chief executive officer, and conducts its clinical development and business activities through operations serving global markets.

View Summit Therapeutics Profile
Earnings Tools